Pharmaceutical Technology
MAY 8, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.
Pharmaceutical Technology
MAY 30, 2023
Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Epcoritamab is set to be launched globally as the first and only bispecific antibody for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 8, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
Drug Discovery World
DECEMBER 16, 2022
A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. . mRNA cancer vaccine meets primary efficacy endpoint . mRNA cancer vaccine meets primary efficacy endpoint . New dermatitis treatment shows promising long-term results .
The Pharma Data
MAY 15, 2023
Safety results through 24 weeks were generally consistent with the known safety profile of Dupixent in its approved dermatology indication. About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
The Pharma Data
DECEMBER 30, 2020
billion acquisition of immuno-oncology company Forty Seven and its lead asset, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). It began in May with the $4.9 Magrolimab targets CD47. But the U.K.-based
The Pharma Data
MARCH 23, 2022
The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities. 11 TREMFYA is approved in the U.S., Source link: [link].
Expert insights. Personalized for you.
246 
Let's personalize your content